INO

Inovio Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.37
-0.60
-3.76%
Pre Market: 15.52 +0.15 +0.98% 04:47 09/25 EDT
OPEN
14.92
PREV CLOSE
15.97
HIGH
16.00
LOW
14.50
VOLUME
13.42M
TURNOVER
--
52 WEEK HIGH
33.79
52 WEEK LOW
1.915
MARKET CAP
2.57B
P/E (TTM)
-9.0625
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Vaccine news roundup - Cuomo sets up panel for separate NY review
Dr. Anthony Fauci took to Facebook Live on Thursday to assuage increasing concerns about a politicized approval process for a potential coronavirus vaccine."People are always saying, 'How do I know
Seekingalpha · 52m ago
White House may overrule tightening of FDA vaccine rules
Reports on Tuesday suggested the FDA was considering stricter guidelines for emergency-use authorization of a coronavirus vaccine, though the White House may not approve of it."It sounds like a political
Seekingalpha · 1d ago
18 ETFs That Could Help You Send Your Kids to College
MotleyFool.com · 1d ago
Inovio Pharma under pressure on bearish Citron call
COVID-19 vaccine developer Inovio Pharmaceuticals ([[INO]] -9.6%) slumps on average volume in apparent response to a post on social media by short seller Citron Research that the stock is heading
Seekingalpha · 1d ago
Now Is the Perfect Time to Invest in Coronavirus Vaccine Stocks
MotleyFool.com · 2d ago
Global vaccine plan gains momentum, U.S. not on board
An $18B initiative to ensure any future vaccine against COVID-19 is fairly shared throughout the world has secured the backing of 156 countries and territories, representing about 64% of the
Seekingalpha · 2d ago
Inovio Defies Market-Wide Weakness: What's Behind The Rally?
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares have been seeing strong momentum ever since hitting a near-term low of $8.78 on Sept. 4.
Benzinga · 3d ago
Are the Gains Over for This Early Leader in the Coronavirus Vaccine Race?
MotleyFool.com · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INO. Analyze the recent business situations of Inovio Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INO stock price target is 19.00 with a high estimate of 36.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 296
Institutional Holdings: 58.12M
% Owned: 34.69%
Shares Outstanding: 167.52M
TypeInstitutionsShares
Increased
73
20.21M
New
125
1.70M
Decreased
30
9.34M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chairman/Independent Director
Simon Benito
Chief Executive Officer/President/Director
Jong Kim
Chief Financial Officer
Peter Kies
Chief Operating Officer
Jacqueline Shea
Chief Operating Officer
Jacqueline Elizabeth Shea
Chief Scientific Officer
Laurent Humeau
Director
David Weiner
Independent Director
Ann Miller
Independent Director
Jay Shepard
Independent Director
Wendy Yarno
Independent Director
Lota Zoth
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About INO
Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Inovio Pharmaceuticals Inc stock information, including NASDAQ:INO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INO stock methods without spending real money on the virtual paper trading platform.